Journal of Hepatology
Volume 51, Issue 6 , Pages 1000-1009 , December 2009

Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV–HCV coinfected patients (ANRS-HC08 “THEVIC” trial)

  • Assia Samri

      Affiliations

    • Inserm, UMRS-945 Laboratoire d’Immunologie Cellulaire et Tissulaire, Centre Hospitalier Pitié-Salpêtrière, 83 Boulevard de l’hôpital, Bâtiment CERVI, 75013 Paris, France
    • UPMC Univ Paris 06, UMRS-945, Laboratoire d’Immunologie Cellulaire et Tissulaire, Paris, France
    • IFR113, Inserm, Laboratoire d’Immunologie Cellulaire et Tissulaire, Paris, France
    • ,
  • Anne-Marie Roque-Afonso

      Affiliations

    • Inserm, U785, Villejuif, France
    • Univ Paris-Sud, UMR-S785, Villejuif, France
    • ,
  • Ondrej Beran

      Affiliations

    • Inserm, UMRS-945 Laboratoire d’Immunologie Cellulaire et Tissulaire, Centre Hospitalier Pitié-Salpêtrière, 83 Boulevard de l’hôpital, Bâtiment CERVI, 75013 Paris, France
    • UPMC Univ Paris 06, UMRS-945, Laboratoire d’Immunologie Cellulaire et Tissulaire, Paris, France
    • Present address: First Faculty of Medicine, Charles University, Prague, Czech Republic.
    • ,
  • Mariagrazia Tateo

      Affiliations

    • Inserm, U785, Villejuif, France
    • Univ Paris-Sud, UMR-S785, Villejuif, France
    • AP-HP Hôpital Paul Brousse, Laboratoire d’Anatomo Pathologie, Villejuif, France
    • ,
  • Elina Teicher

      Affiliations

    • AP-HP Hôpital Paul Brousse, Service Infectiologie, Villejuif, France
    • ,
  • Cyrille Feray

      Affiliations

    • Inserm, CIC4, Nantes, France
    • ,
  • Mylène Sebagh

      Affiliations

    • Inserm, U785, Villejuif, France
    • Univ Paris-Sud, UMR-S785, Villejuif, France
    • AP-HP Hôpital Paul Brousse, Laboratoire d’Anatomo Pathologie, Villejuif, France
    • ,
  • Catherine Guettier

      Affiliations

    • Inserm, U785, Villejuif, France
    • Univ Paris-Sud, UMR-S785, Villejuif, France
    • AP-HP Hôpital Paul Brousse, Laboratoire d’Anatomo Pathologie, Villejuif, France
    • ,
  • Elisabeth Dussaix

      Affiliations

    • AP-HP Hôpital Paul Brousse, Laboratoire de Virologie, Villejuif, France
    • Inserm, U785, Villejuif, France
    • Univ Paris-Sud, UMR-S785, Villejuif, France
    • ,
  • Daniel Vittecoq

      Affiliations

    • Inserm, U785, Villejuif, France
    • Univ Paris-Sud, UMR-S785, Villejuif, France
    • AP-HP Hôpital Paul Brousse, Service Infectiologie, Villejuif, France
    • ,
  • Didier Samuel

      Affiliations

    • Inserm, U785, Villejuif, France
    • Univ Paris-Sud, UMR-S785, Villejuif, France
    • AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France
    • ,
  • Brigitte Autran

      Affiliations

    • Inserm, UMRS-945 Laboratoire d’Immunologie Cellulaire et Tissulaire, Centre Hospitalier Pitié-Salpêtrière, 83 Boulevard de l’hôpital, Bâtiment CERVI, 75013 Paris, France
    • UPMC Univ Paris 06, UMRS-945, Laboratoire d’Immunologie Cellulaire et Tissulaire, Paris, France
    • AP-HP Hôpital Pitié-Salpêtrière, Laboratoire d’Immunologie Cellulaire et Tissulaire, Paris, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 42177481; fax: +33 1 42177490.
    • ,
  • Jean-Charles Duclos-Vallée

      Affiliations

    • Inserm, U785, Villejuif, France
    • Univ Paris-Sud, UMR-S785, Villejuif, France
    • AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France

Received 1 December 2008 ,Revised 5 June 2009 ,Accepted 25 June 2009.

References 

  1. Mauss S, Rockstroh JK. HCV/HIV-coinfection—is there a state of the art after APRICOT and RIBAVIC?. J Antimicrob Chemother. 2005;56:615–618
  2. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34:283–287
  3. Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003;17:1803–1809
  4. Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779–789
  5. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129
  6. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112–116[comment 33]
  7. de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant. 2006;6:2983–2993
  8. Duclos-Vallee JC, Feray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008;47:407–417
  9. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6:578–582
  10. Schulze zur Wiesch J, Lauer GM, Day CL, Kim AY, Ouchi K, Duncan JE, et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol. 2005;175:3603–3613
  11. Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and the outcome of hepatitis C virus infection. Ann Rev Microbiol. 2004;58:391–424
  12. Valiante NM, D’Andrea A, Crotta S, Lechner F, Klenerman P, Nuti S, et al. Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunol Rev. 2000;174:77–89
  13. Rosen HR, Miner C, Sasaki AW, Lewinsohn DM, Conrad AJ, Bakke A, et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology. 2002;35:190–198
  14. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–569
  15. Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology. 1999;117:926–932
  16. Weston SJ, Leistikow RL, Reddy KR, Torres M, Wertheimer AM, Lewinsohn DM, et al. Reconstitution of hepatitis C virus-specific T-cell-mediated immunity after liver transplantation. Hepatology. 2005;41:72–81
  17. Schirren CA, Jung MC, Worzfeld T, Mamin M, Baretton G, Gerlach JT, et al. Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease. J Infect Dis. 2001;183:1187–1194
  18. Lauer GM, Nguyen TN, Day CL, Robbins GK, Flynn T, McGowan K, et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol. 2002;76:2817–2826
  19. Alatrakchi N, Di Martino V, Thibault V, Autran B. Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS. 2002;16:713–717
  20. Valdez H, Carlson NL, Post AB, Asaad R, Heeger PS, Lederman MM, et al. HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. AIDS. 2002;16:1113–1118
  21. Alatrakchi N, Graham CS, He Q, Sherman KE, Koziel MJ. CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV–HIV coinfection versus HCV monoinfection. J Infect Dis. 2005;191:702–709
  22. Kamal SM, Graham CS, He Q, Bianchi L, Tawil AA, Rasenack JW, et al. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis. 2004;189:1140–1150
  23. Morice Y, Roulot D, Grando V, Stirnemann J, Gault E, Jeantils V, et al. Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. J Gen Virol. 2001;82:1001–1012
  24. Teicher E, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A, Boissonnas A, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet. 2007;46:941–952
  25. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–293
  26. Panel I. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25:658–663
  27. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004;38:128–133
  28. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology. 1997;112:1017–1021
  29. Meier V, Burger E, Mihm S, Saile B, Ramadori G. Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection. J Med Virol. 2003;69:50–58
  30. Alatrakchi N, Di Martino V, Thibault V, Benhamou Y, Katlama C, Poynard T, et al. Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection. AIDS. 2004;18:121–123
  31. Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest. 1996;98:1432–1440
  32. Lauer GM, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol. 2005;79:12979–12988
  33. Tsai SL, Sheen IS, Chien RN, Chu CM, Huang HC, Chuang YL, et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci. 2003;10:120–135

☆ The authors who have taken part in this study declared that they do not have anything to declare regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00581-9

doi: 10.1016/j.jhep.2009.06.031

Journal of Hepatology
Volume 51, Issue 6 , Pages 1000-1009 , December 2009

Article Tools

* Image Usage & Resolution